ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

Funding Opportunities.

June 7, 2002

Mayo Clinic’s NCI Designation Extended To Arizona, Florida Sites

July 26, 2002

Advisors Approve NCI Plan To Contract For Early Clinical Trials Of Imaging Agents.

March 31, 2000

Vanderbilt-Ingram wins third SPORE grant.

September 19, 2003

Blistering Resignation Letters Declare CPRIT Outside Mainstream of Science

October 12, 2012